Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
KURA Kura Oncology Inc
- Stocks
- Healthcare
- NASDAQ: KURA
Price (delayed)
$5.765
Market cap
$499.1M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.1
Enterprise value
$467.19M
Tipifarnib, is a potent, selective and orally bioavailable inhibitor of farnesyl transferase in-licensed from Janssen. Previously, tipifarnib was studied in more than 5,000 cancer patients and showed compelling and durable
Highlights
The gross profit has grown by 26% from the previous quarter
Kura Oncology's revenue has increased by 26% from the previous quarter
The company's EPS fell by 4% QoQ but it rose by 3.2% YoY
The quick ratio has plunged by 52% YoY and by 15% from the previous quarter
The equity has contracted by 28% YoY and by 12% from the previous quarter
Key stats
What are the main financial stats of KURA
Market
Valuations
Earnings
Shares outstanding
86.57M
Market cap
$499.1M
Enterprise value
$467.19M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.28
Price to sales (P/S)
7.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.87
Revenue
$67.99M
Gross profit
$67.99M
Operating income
-$203.44M
Net income
-$181.89M
EBIT
-$178.04M
EBITDA
-$177.19M
Free cash flow
$110.55M
Per share
Balance sheet
Liquidity
EPS
-$2.1
EPS diluted
-$2.1
Free cash flow per share
$1.26
Book value per share
$4.51
Revenue per share
$0.78
TBVPS
$8.51
Total assets
$743.76M
Total liabilities
$379.36M
Debt
$19.35M
Equity
$364.41M
Working capital
$634.43M
Debt to equity
0.05
Current ratio
8.07
Quick ratio
7.88
Net debt/EBITDA
0.18
Margins
Efficiency
Dividend
EBITDA margin
-260.6%
Gross margin
100%
Net margin
-267.5%
Operating margin
-299.2%
Return on assets
-29.1%
Return on equity
-43.6%
Return on invested capital
-36.4%
Return on capital employed
-27.2%
Return on sales
-261.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KURA stock price
How has the Kura Oncology stock price performed over time
Intraday
-3.92%
1 week
-10.9%
1 month
-3.43%
1 year
-72.24%
YTD
-33.81%
QTD
-12.65%
Financial performance
How have Kura Oncology's revenue and profit performed over time
Revenue
$67.99M
Gross profit
$67.99M
Operating income
-$203.44M
Net income
-$181.89M
Gross margin
100%
Net margin
-267.5%
The gross profit has grown by 26% from the previous quarter
Kura Oncology's revenue has increased by 26% from the previous quarter
KURA's operating margin is up by 17% since the previous quarter
The net margin is up by 17% since the previous quarter
Price vs fundamentals
How does KURA's price correlate with its fundamentals
Growth
What is Kura Oncology's growth rate over time
Valuation
What is Kura Oncology stock price valuation
P/E
N/A
P/B
1.28
P/S
7.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.87
The company's EPS fell by 4% QoQ but it rose by 3.2% YoY
The stock's P/B is 49% below its 5-year quarterly average of 2.6 and 47% below its last 4 quarters average of 2.5
The equity has contracted by 28% YoY and by 12% from the previous quarter
Kura Oncology's revenue has increased by 26% from the previous quarter
Efficiency
How efficient is Kura Oncology business performance
The company's return on sales rose by 17% QoQ
The return on equity has declined by 16% year-on-year and by 13% since the previous quarter
The ROA has grown by 15% YoY and by 3.6% from the previous quarter
The return on invested capital has increased by 3.7% year-on-year and by 2.2% since the previous quarter
Dividends
What is KURA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KURA.
Financial health
How did Kura Oncology financials performed over time
KURA's total assets is 96% greater than its total liabilities
The current ratio has shrunk by 52% YoY and by 15% QoQ
The quick ratio has plunged by 52% YoY and by 15% from the previous quarter
The debt is 95% smaller than the equity
The debt to equity has surged by 67% year-on-year and by 25% since the previous quarter
The equity has contracted by 28% YoY and by 12% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.